293 related articles for article (PubMed ID: 28800359)
1. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
3. Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.
Vandamme T; Beyens M; de Beeck KO; Dogan F; van Koetsveld PM; Pauwels P; Mortier G; Vangestel C; de Herder W; Van Camp G; Peeters M; Hofland LJ
Br J Cancer; 2016 Mar; 114(6):650-8. PubMed ID: 26978006
[TBL] [Abstract][Full Text] [Related]
4. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
5. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
7. The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Aristizabal Prada ET; Spöttl G; Maurer J; Lauseker M; Koziolek EJ; Schrader J; Grossman A; Pacak K; Beuschlein F; Auernhammer CJ; Nölting S
Endocr Relat Cancer; 2018 Oct; 25(10):893-908. PubMed ID: 29895527
[TBL] [Abstract][Full Text] [Related]
8. Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3Kα-selective Inhibitors in Breast Cancer.
Xu YC; Wang X; Chen Y; Chen SM; Yang XY; Sun YM; Geng MY; Ding J; Meng LH
Theranostics; 2017; 7(4):974-986. PubMed ID: 28382169
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
Yuan Y; Wen W; Yost SE; Xing Q; Yan J; Han ES; Mortimer J; Yim JH
Sci Rep; 2019 May; 9(1):7509. PubMed ID: 31101835
[TBL] [Abstract][Full Text] [Related]
10. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
12. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.
Nölting S; Maurer J; Spöttl G; Aristizabal Prada ET; Reuther C; Young K; Korbonits M; Göke B; Grossman A; Auernhammer CJ
PLoS One; 2015; 10(12):e0143830. PubMed ID: 26636335
[TBL] [Abstract][Full Text] [Related]
13. MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells.
Terracciano F; Capone A; Montori A; Rinzivillo M; Partelli S; Panzuto F; Pilozzi E; Arcidiacono PG; Sette C; Capurso G
Neuroendocrinology; 2021; 111(8):739-751. PubMed ID: 32615570
[TBL] [Abstract][Full Text] [Related]
14. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
Fernandes MS; Melo S; Velho S; Carneiro P; Carneiro F; Seruca R
Oncotarget; 2016 Oct; 7(42):68546-68558. PubMed ID: 27602501
[TBL] [Abstract][Full Text] [Related]
15. Effects of Somatostatin Analogs and Dopamine Agonists on Insulin-Like Growth Factor 2-Induced Insulin Receptor Isoform A Activation by Gastroenteropancreatic Neuroendocrine Tumor Cells.
van Adrichem RC; de Herder WW; Kamp K; Brugts MP; de Krijger RR; Sprij-Mooij DM; Lamberts SW; van Koetsveld PM; Janssen JA; Hofland LJ
Neuroendocrinology; 2016; 103(6):815-25. PubMed ID: 26836610
[TBL] [Abstract][Full Text] [Related]
16. In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer.
Keam B; Kim S; Ahn YO; Kim TM; Lee SH; Kim DW; Heo DS
Anticancer Res; 2015 Jan; 35(1):175-82. PubMed ID: 25550549
[TBL] [Abstract][Full Text] [Related]
17. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
18. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures.
Fankhauser M; Bechmann N; Lauseker M; Goncalves J; Favier J; Klink B; William D; Gieldon L; Maurer J; Spöttl G; Rank P; Knösel T; Orth M; Ziegler CG; Aristizabal Prada ET; Rubinstein G; Fassnacht M; Spitzweg C; Grossman AB; Pacak K; Beuschlein F; Bornstein SR; Eisenhofer G; Auernhammer CJ; Reincke M; Nölting S
Endocrinology; 2019 Nov; 160(11):2600-2617. PubMed ID: 31322702
[TBL] [Abstract][Full Text] [Related]
20. Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pivonello C; Patalano R; Solari D; Auriemma RS; Frio F; Vitulli F; Grasso LFS; Di Cera M; De Martino MC; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Endocrine; 2018 Dec; 62(3):663-680. PubMed ID: 30066286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
